Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 2 3Phase 1/2 3

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 143Myelodysplastic Syndromes 53Leukemia 24Leukemia, Myelomonocytic, Chronic 21Recurrence 12Myeloproliferative Disorders 7Leukemia, Biphenotypic, Acute 7Carcinoma, Non-Small-Cell Lung 7Lymphoma, T-Cell, Peripheral 6Leukemia, Monocytic, Acute 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm, Residual 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myelomonocytic, Acute 5Anemia, Refractory, with Excess of Blasts 5Neoplasms 4Leukemia, Erythroblastic, Acute 4Congenital Abnormalities 4Prostatic Neoplasms 3Primary Myelofibrosis 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Pancreatic Neoplasms 2

Interventions

Cyclophosphamide 155Rituximab 148Etoposide 84fludarabine phosphate 73Peripheral Blood Stem Cell Transplantation 68Mycophenolic Acid 63Busulfan 62Filgrastim 59Melphalan 58Tacrolimus 54Whole-Body Irradiation 51Cytarabine 46fludarabine 45Radiotherapy 43Methotrexate 41Granulocyte Colony-Stimulating Factor 41Cyclosporine 41Vincristine 35Antilymphocyte Serum 35Carmustine 33Doxorubicin 29Prednisone 26Thiotepa 25Bendamustine Hydrochloride 24Methylprednisolone 22Ifosfamide 22Dexamethasone 22thymoglobulin 21sargramostim 20plerixafor 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Non-Hodgkin × Azacitidine × Clear all
NCT03719989 2018-10-25

EPIC

Seoul National University Hospital

Phase 2 Unknown
27 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00543582 2015-07-01

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Mirati Therapeutics Inc.

Phase 2 Terminated
23 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00006019 2013-06-24

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
GenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Leukemia, Monocytic, Acute, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Prostatic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡